MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
11
2018
revised:
28
05
2019
accepted:
17
07
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
11
2
2020
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an incurable cancer of the pleura that can be difficult to diagnose. Biomarkers for an easier and/or earlier diagnosis are needed. Approximately 90% of MPM patients develop a pleural effusion (PE). PEs are ideal sources of biomarkers as the fluid would almost always require drainage for diagnostic and/or therapeutic reasons. However, differentiating MPM PE from PE caused by other diseases can be challenging. MicroRNAs are popular biomarkers given their stable expression in tissue and fluid. MicroRNAs have been analysed in PE cytology samples for the diagnosis of MPM but have not been measured in frozen/fresh PE. We hypothesise that microRNAs expressed in PE are biomarkers for MPM. TaqMan OpenArray was used to analyse over 700 microRNAs in PE cells and supernatants from 26 MPMs and 21 other PE-causing diseases. In PE cells, combining miR-143, miR-210, and miR-200c could differentiate MPM with an area under the curve (AUC) of 0.92. The three-microRNA signature could also discriminate MPM from a further 40 adenocarcinomas with an AUC of 0.9887. These results suggest that the expression of miR-143, miR-210, and miR-200c in PE cells might provide a signature for diagnosing MPM.
Identifiants
pubmed: 31481984
doi: 10.1155/2019/8628612
pmc: PMC6701424
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8628612Déclaration de conflit d'intérêts
No potential conflicts of interest were disclosed.
Références
N Engl J Med. 2005 Oct 13;353(15):1564-73
pubmed: 16221779
Cancer Biol Ther. 2007 Feb;6(2):246-52
pubmed: 17224645
Thorax. 2007 Jul;62(7):569-76
pubmed: 17356060
Clin Cancer Res. 2007 May 15;13(10):2928-35
pubmed: 17504993
Histopathology. 2009 Jan;54(1):55-68
pubmed: 19054156
Annu Rev Biochem. 2010;79:351-79
pubmed: 20533884
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46
pubmed: 20651076
J Mol Diagn. 2010 Nov;12(6):771-9
pubmed: 20864637
J Thorac Oncol. 2011 Mar;6(3):602-5
pubmed: 21266919
Cancer Treat Rev. 2011 Nov;37(7):543-58
pubmed: 21288646
Int J Cancer. 2010 Dec 15;127(12):2859-69
pubmed: 21351265
Arch Pathol Lab Med. 2013 May;137(5):647-67
pubmed: 22929121
N Engl J Med. 2012 Oct 11;367(15):1417-27
pubmed: 23050525
Clin Cancer Res. 2013 Apr 15;19(8):2071-83
pubmed: 23446998
Oncol Rep. 2013 Aug;30(2):535-44
pubmed: 23754129
Am J Cancer Res. 2013 Jun 20;3(3):312-22
pubmed: 23841030
Cell Mol Life Sci. 2014 Aug;71(15):2865-78
pubmed: 24562347
Cancer Res Treat. 2014 Apr;46(2):178-85
pubmed: 24851110
J Mol Diagn. 2014 Jul;16(4):418-30
pubmed: 24912849
Dis Markers. 2014;2014:413946
pubmed: 25505814
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Mol Cancer Res. 2015 Jul;13(7):1106-18
pubmed: 25824152
Biomed Res Int. 2015;2015:125094
pubmed: 25874201
J Thorac Dis. 2015 Jun;7(6):1031-40
pubmed: 26150916
Lung Cancer. 2015 Dec;90(3):457-64
pubmed: 26431916
Cytojournal. 2015 Nov 30;12:26
pubmed: 26681974
Cancer Cytopathol. 2016 Jan;124(1):28-37
pubmed: 26765063
Exp Cell Res. 2016 Feb 15;341(2):218-24
pubmed: 26868304
Ther Adv Respir Dis. 2016 Jun;10(3):275-88
pubmed: 26873306
Biochem Pharmacol. 2017 Jan 1;123:8-18
pubmed: 27431778
Oncotarget. 2016 Dec 20;7(51):84851-84859
pubmed: 27769044
Eur Respir Rev. 2016 Dec;25(142):472-486
pubmed: 27903668
Cancer Cytopathol. 2017 Aug;125(8):635-643
pubmed: 28449331
Oncotarget. 2017 Aug 24;8(44):78193-78207
pubmed: 29100460
Cancers (Basel). 2018 Mar 14;10(3):null
pubmed: 29538329